TABLE 1.
Open in new tab

Demographic and Baseline Data

Patients at Baseline (n = 63; female, 30 [47.6%])
Age (y), minimum-maximum40.5 (21-77)
CD34 (54)
UC29 (46)
Female features, median (IQR)
 Body weight (kg)61.2 (52.7-70)
 Body mass index (kg/m2)22 (20.5-25.5)
 Body surface area (m2)1.68 (1.5-1.8)
 Lean body weight (kg)44.5 (39.1-47.8)
Male features, median (IQR)
 Body weight (kg)77 (70-86.5)
 Body mass index (kg/m2)24 (21.5-27.9)
 Body surface area (m2)1.95 (1.8-2.1)
 Lean body weight (kg)57.2 (56.1-62.9)
Disease features, CD (%)
 Age at diagnosis (y), minimum-maximum27 (11-66)
 A1 (<17)4 (11.7)
 A2 (17-40)22 (64.7)
 A3 (>40)8 (23.5)
 L110 (29.4)
 L27 (20.6)
 L317 (50)
 +L41 (2.9)
 B116 (47.1)
 B28 (23.5)
 B310 (20.4)
 Perianal disease6 (17.6)
 Previous surgery12 (35.3)
Disease features, UC (%)
 Age at diagnosis (y), minimum-maximum34 (12-65)
 E11 (3.4)
 E25 (17.2)
 E314 (48.3)
 E49 (31.1)
Smoking status (%)
Current15 (23.8)
Former7 (11.1)
Never41 (64.1)
Previous exposure to biologics (%)
 Yes/no15 (23.8)/48 (76.2)
 Adalimumab9 (14.3)
 Vedolizumab4 (6.3)
 Golimumab4 (6.3)
Concomitant medications at baseline (%)
 Systemic steroids7 (11.1)
 Oral controlled-release formulation14 (22.2)
 Azathioprine/6-mercaptopurine28 (44.4)
 Methotrexate9 (14.3)
 None19 (30.2)
Clinical and biological data at baseline CD, median (IQR)
 HBI8 (7-10)
 CRP (mg/L)14 (5.9-24)
 FC (µg/g)484 (123-1800)*
 Endoscopy (Simple Endoscopic Score for Crohn Disease)12 (7-20)
Clinical and biological data at baseline UC, median (IQR)
 Partial Mayo score7 (6-9)
 CRP (mg/L)5 (1.6-29.5)
 FC (µg/g)*1698 (226-1800)*
 Endoscopy (Mayo)3 (2-3)
Biological baseline data, median (IQR)
 Albumin (g/dL)40.7 (30.7-44)
 Total protein (g/dL)74 (70-77)
 Leukocytes (mm3)7800 (6720-9770)
 Platelets (mm3)340,000 (275,000-417,000)
Patients at Baseline (n = 63; female, 30 [47.6%])
Age (y), minimum-maximum40.5 (21-77)
CD34 (54)
UC29 (46)
Female features, median (IQR)
 Body weight (kg)61.2 (52.7-70)
 Body mass index (kg/m2)22 (20.5-25.5)
 Body surface area (m2)1.68 (1.5-1.8)
 Lean body weight (kg)44.5 (39.1-47.8)
Male features, median (IQR)
 Body weight (kg)77 (70-86.5)
 Body mass index (kg/m2)24 (21.5-27.9)
 Body surface area (m2)1.95 (1.8-2.1)
 Lean body weight (kg)57.2 (56.1-62.9)
Disease features, CD (%)
 Age at diagnosis (y), minimum-maximum27 (11-66)
 A1 (<17)4 (11.7)
 A2 (17-40)22 (64.7)
 A3 (>40)8 (23.5)
 L110 (29.4)
 L27 (20.6)
 L317 (50)
 +L41 (2.9)
 B116 (47.1)
 B28 (23.5)
 B310 (20.4)
 Perianal disease6 (17.6)
 Previous surgery12 (35.3)
Disease features, UC (%)
 Age at diagnosis (y), minimum-maximum34 (12-65)
 E11 (3.4)
 E25 (17.2)
 E314 (48.3)
 E49 (31.1)
Smoking status (%)
Current15 (23.8)
Former7 (11.1)
Never41 (64.1)
Previous exposure to biologics (%)
 Yes/no15 (23.8)/48 (76.2)
 Adalimumab9 (14.3)
 Vedolizumab4 (6.3)
 Golimumab4 (6.3)
Concomitant medications at baseline (%)
 Systemic steroids7 (11.1)
 Oral controlled-release formulation14 (22.2)
 Azathioprine/6-mercaptopurine28 (44.4)
 Methotrexate9 (14.3)
 None19 (30.2)
Clinical and biological data at baseline CD, median (IQR)
 HBI8 (7-10)
 CRP (mg/L)14 (5.9-24)
 FC (µg/g)484 (123-1800)*
 Endoscopy (Simple Endoscopic Score for Crohn Disease)12 (7-20)
Clinical and biological data at baseline UC, median (IQR)
 Partial Mayo score7 (6-9)
 CRP (mg/L)5 (1.6-29.5)
 FC (µg/g)*1698 (226-1800)*
 Endoscopy (Mayo)3 (2-3)
Biological baseline data, median (IQR)
 Albumin (g/dL)40.7 (30.7-44)
 Total protein (g/dL)74 (70-77)
 Leukocytes (mm3)7800 (6720-9770)
 Platelets (mm3)340,000 (275,000-417,000)

*FC upper limit detection.

TABLE 1.
Open in new tab

Demographic and Baseline Data

Patients at Baseline (n = 63; female, 30 [47.6%])
Age (y), minimum-maximum40.5 (21-77)
CD34 (54)
UC29 (46)
Female features, median (IQR)
 Body weight (kg)61.2 (52.7-70)
 Body mass index (kg/m2)22 (20.5-25.5)
 Body surface area (m2)1.68 (1.5-1.8)
 Lean body weight (kg)44.5 (39.1-47.8)
Male features, median (IQR)
 Body weight (kg)77 (70-86.5)
 Body mass index (kg/m2)24 (21.5-27.9)
 Body surface area (m2)1.95 (1.8-2.1)
 Lean body weight (kg)57.2 (56.1-62.9)
Disease features, CD (%)
 Age at diagnosis (y), minimum-maximum27 (11-66)
 A1 (<17)4 (11.7)
 A2 (17-40)22 (64.7)
 A3 (>40)8 (23.5)
 L110 (29.4)
 L27 (20.6)
 L317 (50)
 +L41 (2.9)
 B116 (47.1)
 B28 (23.5)
 B310 (20.4)
 Perianal disease6 (17.6)
 Previous surgery12 (35.3)
Disease features, UC (%)
 Age at diagnosis (y), minimum-maximum34 (12-65)
 E11 (3.4)
 E25 (17.2)
 E314 (48.3)
 E49 (31.1)
Smoking status (%)
Current15 (23.8)
Former7 (11.1)
Never41 (64.1)
Previous exposure to biologics (%)
 Yes/no15 (23.8)/48 (76.2)
 Adalimumab9 (14.3)
 Vedolizumab4 (6.3)
 Golimumab4 (6.3)
Concomitant medications at baseline (%)
 Systemic steroids7 (11.1)
 Oral controlled-release formulation14 (22.2)
 Azathioprine/6-mercaptopurine28 (44.4)
 Methotrexate9 (14.3)
 None19 (30.2)
Clinical and biological data at baseline CD, median (IQR)
 HBI8 (7-10)
 CRP (mg/L)14 (5.9-24)
 FC (µg/g)484 (123-1800)*
 Endoscopy (Simple Endoscopic Score for Crohn Disease)12 (7-20)
Clinical and biological data at baseline UC, median (IQR)
 Partial Mayo score7 (6-9)
 CRP (mg/L)5 (1.6-29.5)
 FC (µg/g)*1698 (226-1800)*
 Endoscopy (Mayo)3 (2-3)
Biological baseline data, median (IQR)
 Albumin (g/dL)40.7 (30.7-44)
 Total protein (g/dL)74 (70-77)
 Leukocytes (mm3)7800 (6720-9770)
 Platelets (mm3)340,000 (275,000-417,000)
Patients at Baseline (n = 63; female, 30 [47.6%])
Age (y), minimum-maximum40.5 (21-77)
CD34 (54)
UC29 (46)
Female features, median (IQR)
 Body weight (kg)61.2 (52.7-70)
 Body mass index (kg/m2)22 (20.5-25.5)
 Body surface area (m2)1.68 (1.5-1.8)
 Lean body weight (kg)44.5 (39.1-47.8)
Male features, median (IQR)
 Body weight (kg)77 (70-86.5)
 Body mass index (kg/m2)24 (21.5-27.9)
 Body surface area (m2)1.95 (1.8-2.1)
 Lean body weight (kg)57.2 (56.1-62.9)
Disease features, CD (%)
 Age at diagnosis (y), minimum-maximum27 (11-66)
 A1 (<17)4 (11.7)
 A2 (17-40)22 (64.7)
 A3 (>40)8 (23.5)
 L110 (29.4)
 L27 (20.6)
 L317 (50)
 +L41 (2.9)
 B116 (47.1)
 B28 (23.5)
 B310 (20.4)
 Perianal disease6 (17.6)
 Previous surgery12 (35.3)
Disease features, UC (%)
 Age at diagnosis (y), minimum-maximum34 (12-65)
 E11 (3.4)
 E25 (17.2)
 E314 (48.3)
 E49 (31.1)
Smoking status (%)
Current15 (23.8)
Former7 (11.1)
Never41 (64.1)
Previous exposure to biologics (%)
 Yes/no15 (23.8)/48 (76.2)
 Adalimumab9 (14.3)
 Vedolizumab4 (6.3)
 Golimumab4 (6.3)
Concomitant medications at baseline (%)
 Systemic steroids7 (11.1)
 Oral controlled-release formulation14 (22.2)
 Azathioprine/6-mercaptopurine28 (44.4)
 Methotrexate9 (14.3)
 None19 (30.2)
Clinical and biological data at baseline CD, median (IQR)
 HBI8 (7-10)
 CRP (mg/L)14 (5.9-24)
 FC (µg/g)484 (123-1800)*
 Endoscopy (Simple Endoscopic Score for Crohn Disease)12 (7-20)
Clinical and biological data at baseline UC, median (IQR)
 Partial Mayo score7 (6-9)
 CRP (mg/L)5 (1.6-29.5)
 FC (µg/g)*1698 (226-1800)*
 Endoscopy (Mayo)3 (2-3)
Biological baseline data, median (IQR)
 Albumin (g/dL)40.7 (30.7-44)
 Total protein (g/dL)74 (70-77)
 Leukocytes (mm3)7800 (6720-9770)
 Platelets (mm3)340,000 (275,000-417,000)

*FC upper limit detection.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close